Recombinant human hyaluronidase + immune globulin intravenous

( DrugBank: Recombinant human hyaluronidase, Hyaluronidase / KEGG DRUG: Hyaluronidase, Hyaluronidase, Hyaluronidase )

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	1

65. Primary immunodeficiency

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00782106 (ClinicalTrials.gov)	December 4, 2006	29/10/2008	Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV ...	Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up ...	Primary Immunodeficiency Diseases (PID)	Biological: Recombinant human hyaluronidase + immune globulin intravenous	Baxalta now part of Shire	NULL	Completed	16 Years	N/A	All	11	Phase 1/Phase 2	United States

First Previous1Next Last